be less suitable for routine treatment. Also, some patients may benefit more from firm adherence to high-potency dual antiplatelet therapy with either prasugrel or ticagrelor. In the COMPLETE trial, one quarter of the patients received clopidogrel, which may not be the most effective therapy in patients with acute coronary syndromes.10

Should the consistent lack of benefit with respect to all-cause mortality discourage the strategy of routine complete revascularization? Since this strategy appears to be safe and reduces the risk of the composite outcome of cardiovascular death or recurrent myocardial infarction, as well as the risk of future revascularization, it appears to be appropriate to recommend complete revascularization for patients similar to those included in the COMPLETE trial. We hope that the investigators will be able to obtain data from longer follow-up in order to evaluate whether the tendency toward a small reduction in all-cause mortality becomes significant over time. Better selection of high-risk patients may also refine the determination of who is most likely to benefit from complete revascularization. Regardless, in light of the results of the well-planned and well-executed trial by Mehta et al., the guidelines should recommend a strategy of full revascularization in patients with STEMI and multivessel disease, at least in those who have suitable nonculprit lesions.

Disclosure forms provided by the authors are available with the full text of this editorial at NEJM.org.

From the Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen.

This editorial was published on September 1, 2019, at NEJM.org.


DOI: 10.1056/NEJMe1910898
Copyright © 2019 Massachusetts Medical Society.

A Metabolic Vulnerability of Vision

Henna Tyynismaa, Ph.D.

New therapies targeting metabolic vulnerabilities of specific tumor types have created wide interest in recent years. Through research now reported in the Journal by Gantner et al.,1 metabolic precision therapy may become possible in patients with a rare eye disease, macular telangiectasia type 2, which leads to a progressive loss of central vision in both eyes in middle-aged or older persons.2

The macula is the small area in the back of the eye that is responsible for high-resolution (i.e., sharp) vision. In the center of the macula is the fovea, which has the highest density of cone photoreceptor cells and thus, as compared with
other parts of the macula, provides the highest degree of visual resolution. In persons with macular telangiectasia type 2, foveal photoreceptors degenerate, preventing the transduction of light signals to the brain. Telangiectasia refers to small dilated blood vessels, which are secondary abnormalities in this primarily neurodegenerative condition. There is currently no effective treatment for the condition, although encouraging results from a phase 2 trial of a neuroprotective agent, ciliary neurotrophic factor, were reported earlier this year, and an anti–vascular endothelial growth factor drug, bevacizumab, has been found to ameliorate secondary blood-vessel formation.

A genetic component of macular telangiectasia type 2 was suspected, but the combination of genetic heterogeneity and environmental factors affecting the penetrance of genetic effect has made it challenging to establish clear inheritance patterns and to identify disease genes. A genome-wide association study in combination with the analysis of blood metabolites from patients with macular telangiectasia type 2 provided some evidence to support involvement of the serine biosynthesis pathway in conferring susceptibility to the disease. Gantner et al. now report on specific genetic causes of macular telangiectasia type 2: variants in the genes SPTLC1 and SPTLC2, the protein products of which participate in sphingolipid metabolism. (Sphingolipids are a large family of lipids that among other roles, mediate a variety of metabolic, growth, and cell-survival processes.)

It was previously established that pathogenic variation in SPTLC1 and SPTLC2 causes another neurodegenerative disease, hereditary sensory and autonomic neuropathy type 1 (HSAN1), which affects the peripheral nerves and causes sensory abnormalities such as blunted nociception and variable limb weakness. Both genes are needed to make the key enzyme in sphingolipid synthesis, serine palmitoyltransferase (SPT). The etiologic mutations in SPTLC1 and SPTLC2 do not reduce the activity of SPT but instead alter its substrate specificity from serine to alanine. This alteration results in the production and accumulation of deoxysphingolipids, which are neurotoxic.

Having obtained earlier evidence of possible disruption of serine metabolism in persons with macular telangiectasia type 2, with SPTLC1 and SPTLC2 as strong candidate genes, the authors carefully examined 11 patients with HSAN1 for macular telangiectasia type 2–associated macular changes and found such changes in 9 of the patients. Further studies in larger patient cohorts are needed to establish how commonly macular telangiectasia type 2 and sensory neuropathy co-occur. Is macular degeneration typical of all or only specific mutation types? Do any patients with macular telangiectasia type 2 who do not have SPTLC1 or SPTLC2 mutations have neuropathic symptoms? What other monogenic causes (if any) in the same pathway might contribute to macular telangiectasia type 2? Why sensory neurons and foveal photoreceptors are especially vulnerable to elevated levels of deoxysphingolipids is another unanswered question, although a recent study provides a potential clue: the accrual of a specific type of deoxysphingolipid in the mitochondria promotes mitochondrial fission and glucose intolerance. This, in turn, may preferentially compromise the function of cells with high energy requirements, such as neurons (the photoreceptor is a type of neuron).

Gantner et al. went on to analyze 125 persons with macular telangiectasia type 2 who did not test positive for mutations affecting SPT. (As an aside, it seems from the comparatively large size of this group of patients that such mutations cause macular telangiectasia type 2 in a minority of affected persons). However, even in the absence of an SPTLC mutation, aberrant serine metabolism nonetheless appears to have a role in the pathogenesis of disease, because low serine and high deoxysphingolipid levels were found in the blood of the 125 patients with macular telangiectasia type 2 who did not have SPTLC1 or SPTLC2 mutations. The authors suggest that the low serine levels increase deoxysphingolipid levels by reducing substrate availability for SPT as a general mechanism. Testing of a serine-depleted diet in mice supported these findings: elevated levels of deoxysphingolipids developed in the mice, along with retinal and peripheral sensory deficits. Using human retinal organoids, the authors showed that deoxyethylceramides, derivatives of deoxysphingolipids, are toxic to photoreceptors. Inhibition of ceramide synthesis or treatment with fenofibrate to
stimulate deoxysphingolipid degradation prevented death of the photoreceptor cells.

Serine supplementation has been shown to reduce levels of deoxysphingolipids in humans. The results of a randomized, placebo-controlled trial of high-dose serine (400 mg per kilogram of body weight per day) to treat persons with HSAN1 were, without sensitive biomarkers of disease progression, difficult to interpret. The serine–sphingolipid pathway now represents a target for experimental strategies in the treatment of macular telangiectasia type 2, but as the authors rightly caution, it would be premature to prescribe serine or fenofibrate without a better understanding of disease etiology within the broader patient population. In the meantime, patients with HSAN1 should be evaluated for signs of macular telangiectasia type 2, and vice versa.

Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org.

From the Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

This editorial was published on September 11, 2019, at NEJM.org.


Copyright © 2019 Massachusetts Medical Society.